Dasatinib Early Intervention After Cytogenetic or Hematologic Resistance to Imatinib in Patients With Chronic Myeloid Leukemia.

The article presents a study that aims to define the optimal time for starting dasatinib after loss of response on imatinib in patients with chronic myeloid leukemia. The study shows that 72% who got dasatinib after loss of a major cytogenetic response (MCyR) on imatinib attained a complete cytogenetic response (CCyR). It reveals that event-free survival (EFS) was also higher after earlier treatment of dasatinib.